Cardiovascular Diabetology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2021-06-04 145dc5e9m77暂无昵称

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：心血管;糖尿病
经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。

3918 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2020-07-20 jingziwei1988

偏重的研究方向：心血管;代谢综合征
经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么

4088 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2024-05-16 ms4000000140881418 来自广东省

偏重的研究方向：心血管
经验分享：请问大家这个期刊需要查重报告或者润色报告吗

6 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2020-08-04 ms1000001187261143

已经投稿7天了，状态还是new submission，是不是还没到编辑手里？

1572 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2024-05-18 ms9000000045361890 来自安徽省

技术审查都一周了，还没到编辑那里，你们的多久

3 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2024-05-08 ms8000001858743317 来自北京

请问大家现在是先校稿，再付版面费吗？

79 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-11-24 ms6000000946453986 来自山东省

偏重的研究方向：血脂;糖尿病
经验分享：有没有被接受的基础研究文章啊

500 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-12-25 好吃猫111 来自广东省

甲状腺激素的可以投么？

445 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2023-02-07 jaimewang 来自山西省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：内分泌
经验分享：希望今年IF能破10啊

316 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3918, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4088, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205122, encodeId=a3292205122fb, content=偏重的研究方向：心血管 经验分享：请问大家这个期刊需要查重报告或者润色报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7808745235, createdName=ms4000000140881418, createdTime=Thu May 16 23:35:21 CST 2024, time=2024-05-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=806062, encodeId=bd2080606287, content=已经投稿7天了，状态还是new submission，是不是还没到编辑手里？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1572, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd1f5408686, createdName=ms1000001187261143, createdTime=Tue Aug 04 09:40:31 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205407, encodeId=8acd220540ec2, content=技术审查都一周了，还没到编辑那里，你们的多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sat May 18 21:20:40 CST 2024, time=2024-05-18, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2203457, encodeId=5dd8220345e9e, content=请问大家现在是先校稿，再付版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed May 08 15:16:58 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=445, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2113542, encodeId=c5a921135427d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：内分泌 经验分享：希望今年IF能破10啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=316, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230208/4599f92647c84b469b139f6bf5fa7d1e/523a898550c74e6b92500c9b789a1bf1.jpg, createdBy=ecc52539451, createdName=jaimewang, createdTime=Tue Feb 07 22:22:39 CST 2023, time=2023-02-07, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2099530, encodeId=7a782099530ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=561, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epppOIrNy2qINgw0MtwMndODj7SAwAxm5LjuR7Dvtaa0TvghVBPeCTOWaHTTnvodLk91H97LzuPibg/132, createdBy=ff912327695, createdName=木帆, createdTime=Thu Nov 10 01:08:02 CST 2022, time=2022-11-10, status=1, ipAttribution=)]

2022-11-10 木帆

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：心血管;糖尿病
经验分享：杂志效率很高，投稿到录用一个月内，外审意见很专业，统计分析要求比较高

561 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务